دورية أكاديمية
أعرض في EDS

Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products.

التفاصيل البيبلوغرافية
العنوان: Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products.
المؤلفون: Hino C; Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Pham B; Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Park D; Department of Internal Medicine, School of Medicine, University of California San Francisco-Fresno, Fresno, CA 93701, USA., Yang C; Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA 92521, USA., Nguyen MHK; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Kaur S; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Reeves ME; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Xu Y; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Nishino K; Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Pu L; Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Kwon SM; Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Zhong JF; Department of Basic Sciences, Loma Linda University, Loma Linda, CA 92354, USA., Zhang KK; Department of Nutrition, Texas A&M University, College Station, TX 77030, USA.; Center for Epigenetics & Disease Prevention, Institute of Biosciences & Technology, College of Medicine, Texas A&M University, Houston, TX 77030, USA., Xie L; Department of Nutrition, Texas A&M University, College Station, TX 77030, USA.; Center for Epigenetics & Disease Prevention, Institute of Biosciences & Technology, College of Medicine, Texas A&M University, Houston, TX 77030, USA., Chong EG; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Chen CS; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Nguyen V; Department of Biology, University of California Riverside, Riverside, CA 92521, USA., Castillo DR; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA., Cao H; Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
المصدر: Biomedicines [Biomedicines] 2022 Jun 14; Vol. 10 (6). Date of Electronic Publication: 2022 Jun 14.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: The tumor microenvironment (TME) plays an essential role in the development, proliferation, and survival of leukemic blasts in acute myeloid leukemia (AML). Within the bone marrow and peripheral blood, various phenotypically and functionally altered cells in the TME provide critical signals to suppress the anti-tumor immune response, allowing tumor cells to evade elimination. Thus, unraveling the complex interplay between AML and its microenvironment may have important clinical implications and are essential to directing the development of novel targeted therapies. This review summarizes recent advancements in our understanding of the AML TME and its ramifications on current immunotherapeutic strategies. We further review the role of natural products in modulating the TME to enhance response to immunotherapy.
References: PLoS One. 2012;7(1):e29794. (PMID: 22272248)
Clin Nutr. 2017 Apr;36(2):542-551. (PMID: 26899917)
Stem Cell Res Ther. 2021 Aug 20;12(1):465. (PMID: 34412685)
Int J Hematol. 2013 Nov;98(5):558-62. (PMID: 24142765)
Front Immunol. 2021 Apr 27;12:665541. (PMID: 33986753)
Biomed Pharmacother. 2020 May;125:109885. (PMID: 32007917)
Cancer Prev Res (Phila). 2014 Dec;7(12):1240-50. (PMID: 25293876)
Leuk Res. 2018 Mar;66:1-7. (PMID: 29331774)
Nutrients. 2019 Nov 17;11(11):. (PMID: 31744219)
Cancer Treat Rep. 1985 Dec;69(12):1399-407. (PMID: 2416438)
Sci Transl Med. 2015 May 20;7(288):288ra78. (PMID: 25995224)
N Engl J Med. 1999 Sep 30;341(14):1051-62. (PMID: 10502596)
Front Immunol. 2019 Oct 11;10:2357. (PMID: 31681270)
Immunity. 2000 Aug;13(2):265-76. (PMID: 10981969)
Leukemia. 1989 Jul;3(7):469-74. (PMID: 2659901)
Curr Hematol Malig Rep. 2018 Dec;13(6):417-425. (PMID: 30280288)
Nature. 2013 Aug 8;500(7461):222-6. (PMID: 23812591)
Cell. 2018 May 31;173(6):1439-1453.e19. (PMID: 29856956)
Cell Rep. 2020 Jan 21;30(3):739-754.e4. (PMID: 31968250)
Acta Biochim Pol. 2002;49(2):393-406. (PMID: 12362981)
J Hematol Oncol. 2015 Jul 30;8:93. (PMID: 26219463)
Blood. 2009 Oct 29;114(18):3909-16. (PMID: 19710498)
Mol Ther. 2013 Nov;21(11):2122-9. (PMID: 23831595)
PLoS One. 2013 Jun 20;8(6):e65998. (PMID: 23840388)
Br J Cancer. 2011 Jun 28;105(1):93-103. (PMID: 21629244)
Blood. 2009 Oct 29;114(18):3793-802. (PMID: 19724059)
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211002647. (PMID: 33754891)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
Nutrients. 2019 May 03;11(5):. (PMID: 31058874)
Curr Opin Oncol. 2007 Mar;19(2):142-7. (PMID: 17272987)
Cancers (Basel). 2021 Oct 19;13(20):. (PMID: 34680392)
Leuk Res. 2015 Feb;39(2):257-62. (PMID: 25542695)
Gene. 2018 Jan 5;638:20-25. (PMID: 28951311)
Anticancer Res. 2012 Jul;32(7):2905-13. (PMID: 22753754)
Int J Mol Sci. 2020 Apr 21;21(8):. (PMID: 32326335)
Blood. 2017 Mar 30;129(13):1791-1801. (PMID: 28126925)
J Immunol. 2001 Nov 15;167(10):6021-30. (PMID: 11698483)
Cancer Lett. 2020 Nov 1;492:96-105. (PMID: 32860849)
J Clin Oncol. 2010 Jan 1;28(1):105-13. (PMID: 19917869)
Blood. 2013 Aug 1;122(5):749-58. (PMID: 23733335)
Blood Cancer J. 2014 Jun 13;4:e218. (PMID: 24927407)
Cancer Res. 2017 Jan 15;77(2):303-311. (PMID: 27872094)
Nat Rev Immunol. 2012 Mar 22;12(4):269-81. (PMID: 22437939)
J Hematol Oncol. 2021 May 25;14(1):82. (PMID: 34034795)
Leukemia. 2022 Jan;36(1):13-22. (PMID: 34302116)
Blood. 2014 Apr 10;123(15):2343-54. (PMID: 24596416)
Int J Cancer. 2011 Sep 15;129(6):1373-81. (PMID: 21105040)
Clin Cancer Res. 2009 May 15;15(10):3325-32. (PMID: 19417016)
J Exp Clin Cancer Res. 2018 Nov 19;37(1):277. (PMID: 30454068)
Proc Natl Acad Sci U S A. 1990 May;87(10):3929-32. (PMID: 2339131)
Nutr Cancer. 2016;68(3):530-4. (PMID: 27008503)
Blood. 2007 Jan 1;109(1):323-30. (PMID: 16940427)
Blood. 2021 Feb 11;137(6):751-762. (PMID: 32929488)
Science. 1986 Sep 19;233(4770):1318-21. (PMID: 3489291)
J Clin Invest. 2003 Nov;112(9):1437-43. (PMID: 14597769)
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. (PMID: 28741618)
Oncology. 2008;75(3-4):203-14. (PMID: 18852491)
Clin Transl Immunology. 2019 May 05;8(5):e1046. (PMID: 31073403)
Front Immunol. 2017 Feb 09;8:106. (PMID: 28232835)
Blood. 2014 May 1;123(18):2816-25. (PMID: 24574459)
Science. 2002 Mar 15;295(5562):2097-100. (PMID: 11896281)
Leuk Lymphoma. 2008 Jan;49(1):134-48. (PMID: 17926185)
Oncol Rev. 2018 Oct 08;12(2):366. (PMID: 30405894)
Crit Rev Oncol Hematol. 2021 Jan;157:103164. (PMID: 33271388)
Cancer Discov. 2019 Mar;9(3):370-383. (PMID: 30409776)
N Engl J Med. 2016 Dec 8;375(23):2255-2262. (PMID: 27959684)
Nat Med. 2018 May;24(5):541-550. (PMID: 29686425)
Br J Haematol. 2015 Sep;170(5):704-18. (PMID: 25974135)
Am J Cancer Res. 2017 May 01;7(5):1016-1036. (PMID: 28560055)
Front Oncol. 2020 May 06;10:697. (PMID: 32435621)
Haematologica. 2016 Oct;101(10):1216-1227. (PMID: 27390361)
Blood. 2005 Jun 1;105(11):4163-9. (PMID: 15687234)
Annu Rev Immunol. 1990;8:111-37. (PMID: 2188660)
Genes Dev. 1996 Jan 15;10(2):142-53. (PMID: 8566748)
Nat Med. 2018 Jun;24(6):724-730. (PMID: 29867227)
Int J Clin Pharmacol Res. 1993;13(1):21-7. (PMID: 8509233)
Transl Oncol. 2020 Dec;13(12):100869. (PMID: 32956997)
Int J Mol Sci. 2019 Nov 28;20(23):. (PMID: 31795243)
J Cell Mol Med. 2008 Apr;12(2):690-700. (PMID: 18419605)
Blood. 2013 Nov 14;122(20):3461-72. (PMID: 24016461)
Front Oncol. 2021 Mar 11;11:632623. (PMID: 33777786)
Blood Adv. 2018 Feb 27;2(4):335-346. (PMID: 29449224)
Int J Hematol. 2015 Nov;102(5):579-86. (PMID: 26358057)
Trends Immunol. 2002 Nov;23(11):549-55. (PMID: 12401408)
Leuk Res. 2010 May;34(5):553-65. (PMID: 19811822)
J Immunother Cancer. 2018 Nov 5;6(1):116. (PMID: 30396365)
Arch Surg. 1990 Feb;125(2):200-5. (PMID: 1689143)
Front Immunol. 2018 Sep 03;9:1971. (PMID: 30233577)
Nature. 2019 Aug;572(7768):254-259. (PMID: 31316209)
N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137)
Front Immunol. 2017 May 29;8:573. (PMID: 28611767)
Int J Oncol. 2021 Aug;59(2):. (PMID: 34278453)
Lancet Haematol. 2019 Sep;6(9):e480-e488. (PMID: 31400961)
Blood. 2005 Feb 15;105(4):1815-22. (PMID: 15494428)
Blood. 2006 Mar 1;107(5):1878-87. (PMID: 16282345)
Front Cell Dev Biol. 2021 Jun 24;9:692800. (PMID: 34249942)
Exp Hematol. 2017 Jun;50:1-12. (PMID: 28174131)
J Immunol. 2015 Sep 15;195(6):2580-90. (PMID: 26246143)
Biochem Soc Trans. 2016 Apr 15;44(2):406-11. (PMID: 27068947)
Leukemia. 2002 Sep;16(9):1713-24. (PMID: 12200686)
Int J Cancer. 2015 Nov 15;137(10):2384-93. (PMID: 25866142)
Life (Basel). 2021 May 23;11(6):. (PMID: 34071099)
Annu Rev Med. 2013;64:71-90. (PMID: 23092383)
J Clin Med. 2015 Mar 25;4(4):504-34. (PMID: 26239344)
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. (PMID: 21498393)
J Clin Med. 2020 May 18;9(5):. (PMID: 32443460)
Front Pharmacol. 2014 Oct 28;5:235. (PMID: 25389405)
Front Oncol. 2021 Feb 16;10:593848. (PMID: 33680923)
Cell Physiol Biochem. 2018;48(5):2061-2073. (PMID: 30099447)
Leuk Lymphoma. 2008 Jan;49(1):57-61. (PMID: 18203012)
Nutrients. 2013 Sep 09;5(9):3496-505. (PMID: 24022818)
Neoplasia. 2021 Dec;23(12):1252-1260. (PMID: 34775232)
Mutagenesis. 2021 Nov 29;36(6):419-428. (PMID: 34505878)
Front Oncol. 2019 Oct 25;9:1135. (PMID: 31709192)
Gene Ther. 2010 May;17(5):678-86. (PMID: 20200563)
Curr Drug Targets. 2017;18(3):296-303. (PMID: 25706110)
Sci Rep. 2018 Feb 22;8(1):3459. (PMID: 29472583)
Nat Rev Immunol. 2018 Jun;18(6):363-373. (PMID: 29520044)
Adv Pharm Bull. 2015 Sep;5(3):299-304. (PMID: 26504750)
J Exp Med. 2003 Dec 15;198(12):1875-86. (PMID: 14676299)
Blood Cancer J. 2021 Feb 22;11(2):41. (PMID: 33619261)
Exp Hematol. 2001 Apr;29(4):448-57. (PMID: 11301185)
Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. (PMID: 30518633)
Blood. 2014 May 8;123(19):3016-26. (PMID: 24652987)
Chin J Integr Med. 2020 May;26(5):339-344. (PMID: 31848890)
Oncol Res. 2016;24(4):215-23. (PMID: 27656831)
Cancer Cell. 2020 Jan 13;37(1):71-84.e7. (PMID: 31935373)
Semin Cancer Biol. 2015 Dec;35 Suppl:S199-S223. (PMID: 25865775)
Molecules. 2021 May 05;26(9):. (PMID: 34063044)
N Engl J Med. 2016 Jul 14;375(2):143-53. (PMID: 27410923)
Leuk Res Treatment. 2012;2012:125814. (PMID: 23198150)
Int J Hematol Oncol Stem Cell Res. 2017 Jul 1;11(3):209-216. (PMID: 28989587)
J Exp Med. 1999 Dec 6;190(11):1583-94. (PMID: 10587349)
Biomedicines. 2022 Apr 30;10(5):. (PMID: 35625776)
Br J Cancer. 2017 Aug 8;117(4):451-460. (PMID: 28704840)
Cancer Manag Res. 2019 Apr 12;11:3187-3196. (PMID: 31114360)
Clin Epigenetics. 2019 Oct 17;11(1):143. (PMID: 31623675)
Blood. 2011 Jun 2;117(22):5816-26. (PMID: 21398578)
Oncoimmunology. 2018 Jul 11;7(9):e1469594. (PMID: 30228937)
Phytother Res. 2018 Aug;32(8):1636-1641. (PMID: 29701283)
J Transl Med. 2013 Dec 04;11:298. (PMID: 24304929)
Int J Cancer. 2019 Oct 15;145(8):2201-2208. (PMID: 30485425)
Cell Cycle. 2006 Feb;5(4):447-51. (PMID: 16479173)
Clin Cancer Res. 2014 Mar 1;20(5):1135-45. (PMID: 24284058)
Front Oncol. 2021 Aug 23;11:709543. (PMID: 34497762)
Drug Des Devel Ther. 2016 Feb 04;10:557-70. (PMID: 26893544)
J Cell Biochem. 2008 Apr 1;103(5):1551-72. (PMID: 17879954)
فهرسة مساهمة: Keywords: acute myeloid leukemia; immunotherapy; natural products; tumor microenvironment
تواريخ الأحداث: Date Created: 20220624 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9219790
DOI: 10.3390/biomedicines10061410
PMID: 35740430
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines10061410